Nykänen P, Sten T, Jürjenson H, Veski P, Marvola M
Division of Biopharmaceutics and Pharmacokinetics, Department of Pharmacy, University of Helsinki, Finland.
Pharmazie. 2004 Apr;59(4):268-73.
Colon-specific drug-delivery systems have been extensively investigated over the last decade. The aim of the study reported here was to investigate whether times of commencement of drug liberation and absorption could be controlled by varying the amount of citric acid in granule cores or in the tablet matrix in enteric-coated multiple-unit tablets. One of the most important aims was to determine the optimal amounts and locations of citric acid in formulations intended as drugs targeted at the colon. Ibuprofen was used as the model drug. Drug release rates were studied in phosphate buffer at pH 6.8 and 7.4. A gradient dissolution study at pH 1.2, 6.8 and 7.4 was undertaken with two formulations. Drug absorption was studied by means of bioavailability tests. We concluded that the drug release rate could be controlled in vitro by changing the amount of citric acid in granule cores or the tablet matrix. In vivo tests confirmed that between 10 and 15% citric acid in the tablet matrix delayed the commencement of drug absorption most. This kind of formulations could be suitable for preparation of colon-specific dosage forms. It is probably unnecessary to include citric acid in granule cores. No logical correlation between in vitro and in vivo results was obtained.
在过去十年中,结肠特异性给药系统得到了广泛研究。本文报道的这项研究的目的是探究是否可以通过改变肠溶包衣多单元片剂颗粒核心或片剂基质中柠檬酸的含量来控制药物释放和吸收的起始时间。最重要的目标之一是确定在旨在靶向结肠的制剂中柠檬酸的最佳含量和位置。布洛芬用作模型药物。在pH 6.8和7.4的磷酸盐缓冲液中研究了药物释放速率。对两种制剂进行了在pH 1.2、6.8和7.4下的梯度溶出研究。通过生物利用度试验研究了药物吸收情况。我们得出结论,通过改变颗粒核心或片剂基质中柠檬酸的含量,可以在体外控制药物释放速率。体内试验证实,片剂基质中10%至15%的柠檬酸最能延迟药物吸收的起始时间。这种制剂可能适合制备结肠特异性剂型。可能没有必要在颗粒核心中包含柠檬酸。体外和体内结果之间未获得逻辑相关性。